Remarks

Claims 1-52 are pending.

Response to Restriction Requirement

The Office Action requires restriction to one of the following twenty-two groups.

Group I, claims 1-5, drawn to a method of screen a subject for breast cancer comprising assaying for the presence of androgen receptor protein. Claims 1-5 will be examined with this Group to the extent an antibody is used to detect the androgen receptor.

Group II, claims 1-10, drawn to a method of screen a subject for breast cancer comprising assaying for the presence of androgen receptor mRNA. Claims 1-5 will be examined with this Group to the extent a nucleic acid probe is used to detect the androgen receptor.

Group III, claims 11-14, 16, 18, 23 and 24, drawn to a method of treating cancer comprising administering an androgen receptor inhibitor, wherein the inhibitor comprises ARA67. Claims 11, 12, 14, 16, 18, 23 and 24 will be examined with the instant Group to the extenet ARA67 is administered to a subject.

Group IV, claims 11, 12, 14-16, 18, 23 and 24, drawn to a method of treating cancer comprising administering an androgen receptor inhibitor, wherein the inhibitor comprises GSK2B. Claims 11, 12, 14, 16, 18, 23 and 24 will be examined with the instant Group to the extent GSK2B is administered to a subject.

Group V, claims 11, 12, 14, 16-18, 23 and 24, drawn to a method of treating cancer comprising administering an androgen receptor inhibitor, wherein the inhibitor comprises hRad9. Claims 11, 12, 14, 16, 18, 23 and 24 will be examined with the instant Group to the extent hRad9 is administered to a subject.

Group VI, claims 11 and 19-24, drawn to a method of treating cancer comprising administering an androgen receptor inhibitor, wherein the inhibitor is a functional nucleic acid, SEQ ID NO:11. Claims 11, 23 and 24 will be examined with the instant Group to the extent a siRNA is administered to a subject.

Group VII, claims 25-30, drawn to a method of screen a composition for the ability to modulate androgen receptor (AR) activity comprising administering the compound to a system.

Group VIII, claims 31 and 32, drawn to a composition for inhibiting androgen receptor activity comprising a molecule, which is not SEQ ID NO:1. NOTE: Claim 32 reading on ARA67 will be examined only with the instant Group to the extent the species elected is a protein/peptide.

Group IX, claims 33 and 34, drawn to a composition for inhibiting androgen receptor activity comprising a molecule, which is not SEQ ID NO:7. NOTE: Claim 33 reading on hRad9 will be examined only with the instant Group to the extent the species elected is a protein/peptide.

Group X, claims 35-37, drawn to a composition inhibiting androgen receptor activity comprising a functional nucleic acid, a siRNA comprising SEQ ID NO:11.

Group XI, claims 38, 41 and 44-46, drawn to a composition for inhibiting androgen receptor activity comprising an antibody, wherein the molecule competes with ARA67 for binding to AR and is not SEQ ID NO:1. Claims 38 and 41 will be examined with Group XI to the extent the composition comprises an antibody.

Group XII, claims 38, 41, 47 and 48, drawn to a composition for inhibiting androgen receptor activity comprising a functional nucleic acid, wherein the molecule competes with ARA67 for binding to AR and is not SEQ ID NO:1. Claims 38 and 41 will be examined with Group XII to the extent the composition comprises a functional nucleic acid.

Group XIII, claims 39 and 42, drawn to a composition for inhibiting androgen receptor activity comprising an antibody, wherein the molecule competes with hRad9 for binding to AR and is not SEQ ID NO:7. Claims 39 and 42 will be examined with Group XIII to the extent the composition comprises an antibody.

Group XIV, claims 39 and 42, drawn to a composition for inhibiting androgen receptor activity comprising a molecule, wherein the molecule competes with hRad9 for binding to AR and is not SEQ ID NO:7. Claims 39 and 42 will be examined with Group XIV to the extent the composition comprises a functional nucleic acid.

Group XV, claim 40, drawn to a composition for inhibiting androgen receptor activity comprising an antibody, wherein the molecule competes with GSK2B for binding to AR and is not SEQ ID NO:5. Claim 40 will be examined with Group XV to the extent the composition comprises an antibody.

Group XVI, claim 40, drawn to a composition for inhibiting androgen receptor activity comprising a functional nucleic acid, wherein the molecule competes with GSK2B for binding to AR and is not SEQ ID NO:5. Claim 40 will be examined with Group XVI to the extent the composition comprises a functional nucleic acid.

Group XVII, claim 43, drawn to a composition for inhibiting androgen receptor activity comprising an antibody, wherein the composition binds AR and is not SEQ ID NO:5. Claim 43 will be examined with the instant Group to the extent the composition comprises an antibody.

Group XVIII, claim 43, drawn to a composition for inhibiting androgen receptor activity comprising a functional nucleic acid, wherein the composition binds AR and is not SEQ ID NO:5. Claim 43 will be examined with the instant Group to the extent the composition comprises a functional nucleic acid.

Group XIX, claim 49, drawn to a compound produced by the method of screening a compound for the ability to modulate AR activity comprising administering compound that decreases the amount of phosphorylated AR.

Group XX, claim 50, drawn to a compound produced by the method of screening a compound for ability to modulate AR activity comprising administering compound that decreases the amount of nuclear AR.

Group XXI, claim 51, drawn to a compound produced by the method of screening a compound for ability to modulate AR activity comprising administering compound that decreases the amount of phosphorylated AR.

Group XXII, claim 52, drawn to a compound produced by the method of screening a compound for ability to modulate AR activity comprising administering compound that decreases the amount of N-terminus AR interacting with the C-terminus of AR.

In response, applicants elect Group I (claims 1-5) with traverse. Aplicants believe the rejection is not proper and request that the restriction be withdrawn. The Examiner's rejection is based on the disclosure of Fujimoto et al., Lab Invest. 2000 Sep;80(9):1465-71 disclosing the technical feature of claim 1. Fujimoto et al. does not disclose "a method of screening a subject for breast cancer comprising a) obtaining a tissue sample, and b) assaying for the presence of androgen receptor, wherein the presence of androgen receptor indicates an increased risk of or presence of breast cancer. At best, Fujimoto et al. indicates that androgen receptor is expressed in certain breast cancers. Likewise, the Examiner's rejection relies on Moinfar et al., Cancer 98(4): 703-711 (2003). Moinfar et al. concludes "Androgen receptors are commonly expressed in DCIS and in invasive breast carcinoma. A significant number of poorly differentiated

carcinomas are ER-negative and PR-negative but AR-positive." (Abstract) This conflusion does not disclosed the technical feature of claim 1, as dicussed herein.

Therefore, Applicants respectfully request removal of the Unity Rejection under PCT 13.1 as the claim 1 technical feature is not found in the art.

A deposit order account charge made electronically in the amount of $65.00, representing $65.00 for the fee for a small entity under 37 C.F.R. § 1.17(a)(1) and a Request for Extension of Time under 37 CFR 1.136 for a one month extension of time are enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-4667.

Respectfully submitted,

ARNALL GOLDEN GREGORY LLP

/David E. Huizenga/

David E. Huizenga, Ph.D.
Registration No. 49,026

ARNALL GOLDEN GREGORY LLP
(404) 873-8500
(404) 873-8501 (fax)
Customer No.: 53449